Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma

I. Hoof (Hørsholm, Denmark), M. Witten (Hørsholm, Denmark), T. Stranzl (Hørsholm, Denmark), S. Brand (Hørsholm, Denmark), M. Shamji (London, United Kingdom), E. Bateman (Cape Town, South Africa), E. Bleecker (Tucson, United States of America), P. Andersen (Hørsholm, Denmark)

Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Session: Asthma clinical trials and real-life studies
Session type: E-poster
Number: 877

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
I. Hoof (Hørsholm, Denmark), M. Witten (Hørsholm, Denmark), T. Stranzl (Hørsholm, Denmark), S. Brand (Hørsholm, Denmark), M. Shamji (London, United Kingdom), E. Bateman (Cape Town, South Africa), E. Bleecker (Tucson, United States of America), P. Andersen (Hørsholm, Denmark). Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma. 877

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
House dust mite sublingual immunotherapy reduces type 2 biomarkers in allergic asthma
Source: Virtual Congress 2020 – Management of allergy, asthma and COPD
Year: 2020


Impact of asthma-associated genetic polymorphisms on the efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma
Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science
Year: 2021



Diagnostic utility of serum periostin for house dust mite sublingual immunotherapy response in allergic rhinitis
Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials
Year: 2021


Sublingual immunotherapy is an established therapy for house dust mite sensitive allergic rhinitis and/or asthma
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007


Clinical efficiency of sublingual and subcutaneous allergenspecific immunotherapy with household dust mite allergen in patients with persistent allergic rhinitis
Source: Eur Respir J 2006; 28: Suppl. 50, 438s
Year: 2006

Effect of house dust mite sublingual immunotherapy on airway inflammation and remodeling in allergic asthma with rhinitis
Source: International Congress 2019 – Precision meets immunology in treatment of airway diseases
Year: 2019




Safety of subcutaneous immunotherapy with standardized extracts of house dust mite in allergic asthmatic subjects
Source: Eur Respir J 2002; 20: Suppl. 38, 57s
Year: 2002

Efficacy of specific allergy vaccination in house dust mite asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 465s
Year: 2005

Oral presentation: Early sources of IL-13 in house dust mite-induced neonatal allergic airways disease
Source: Lung Science Conference 2013 - Early origins and mechanisms of chronic lung disease
Year: 2013

Effects of 3-yr immunotherapy with standardised extracts of house dust mite in allergic asthmatic subjects receiving appropriate drug treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 107s
Year: 2002

Association between dust mite sensitisation and asthma severity
Source: Annual Congress 2010 - Clinical aspects of asthma and allergic respiratory diseases
Year: 2010

Circulating platelets activity in patients sensitised to house dust mite suffering from persistent allergic rhinitis with or without asthma symptoms
Source: Eur Respir J 2005; 26: Suppl. 49, 590s
Year: 2005

Hypoallergenic high dose scit as add-on therapy in children with allergic asthma caused by house dust mites
Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases
Year: 2009


Allergen exposure in nondog and nonhouse dust mite sensitized atopic asthmatic subjects; effect on bronchial reactivity
Source: Eur Respir J 2001; 18: Suppl. 33, 482s
Year: 2001

The effect of BCG treatment on the remodelling in the house dust mite induced allergic asthma in mice
Source: Eur Respir J 2005; 26: Suppl. 49, 580s
Year: 2005

OPURIT: Omalizumab-protected ultra rush specific immunotherapy in severe asthmatic patients with house dust mite allergy
Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Year: 2011


Calcaratarin D attenuates house dust mite-induced allergic asthma
Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science
Year: 2021


Sensitisation to house dust mite: its association with bronchial hyperresponsiveness and lung function in asthmatic children
Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma
Year: 2009

Specific allergen immunotherapy of asthma combined with allergic rhinitis
Source: Eur Respir J 2006; 28: Suppl. 50, 441s
Year: 2006

Evaluation of six-year allergen immunotherapy in allergic rhinitis and allergic asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 439s
Year: 2006